Dear Colleagues,

we cordially invite you to attend the Lp(a) Update, taking place on 26–27 June 2026 at the Alte Kongresshalle in Munich, Germany.

Lp(a): Between Myth and Clinical Reality

With the Lp(a) Update 2026, we aim to offer a slightly different kind of scientific meeting. Although lipoprotein(a) is a well-established cardiovascular risk factor, many myths still persist. At the same time, clinicians are faced with very practical questions in everyday practice—questions we would like to address together.

Leading national and international experts will present the latest insights into lipoprotein(a). In addition, we will discuss your questions and jointly explore how to manage the finding of “elevated Lp(a)” in clinical practice and what this means for cardiovascular risk management.

Current and Future Therapeutic Options

Lipoprotein apheresis remains the treatment of choice for high-risk patients with elevated Lp(a). At the same time, new lipid-lowering therapies are under development, and promising study results are eagerly anticipated. We will discuss currently available treatment options, analytical and diagnostic challenges, and new clinical data in an open and interactive exchange.

Join us and take part in the discussion—we very much look forward to welcoming you in Munich.

Professor Oliver Weingärtner, MD
Chair, DGFL – Lipid League

Anja Vogt, MD
Vice Chair, DGFL – Lipid League